Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Zijlstra

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Drugs & Aging|November 23, 2016
A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes MellitusTim Heise, Ulrike Hövelmann, Eric Zijlstra, et al.
Journal of Diabetes Science and Technology|November 3, 2022
An Investigation Into Local Infusion Site Pain After Infusion of Ultra Rapid Lispro Excipients Across Sites and DepthsDebra Ignaut, Tsuyoshi Fukuda, Ramanjineyulu Bandi, et al.
Diabetes, Obesity & Metabolism|February 21, 2024
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetesUlrike Hövelmann, Susanne Engberg, Tim Heise, et al.
Clinical Pharmacokinetics|November 24, 2016
Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes MellitusTim Heise, Kirstine Stender-Petersen, Ulrike Hövelmann, et al.
Journal of Diabetes Science and Technology|April 27, 2023
Noninvasive Continuous Glucose Monitoring With a Novel Wearable Dial Resonating Sensor: A Clinical Proof-of-Concept StudyConsuelo Handy, Mohamed Sabih Chaudhry, Muhammad Rafaqat Ali Qureshi, et al.
Journal of Diabetes Science and Technology|December 28, 2022
Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 DiabetesParag Garhyan, Edward Pratt, Oliver Klein, et al.
Clinical Therapeutics|September 9, 2020
Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy SubjectsJennifer Leohr, Mary Anne Dellva, Elizabeth LaBell, et al.
Diabetology & Metabolic Syndrome|December 5, 2017
Poor glycaemic control is associated with reduced exercise performance and oxygen economy during cardio-pulmonary exercise testing in people with type 1 diabetesOthmar Moser, Max L Eckstein, Olivia McCarthy, et al.
Diabetes, Obesity & Metabolism|October 10, 2023
Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusionJennifer Leohr, Mary Anne Dellva, Elizabeth LaBell, et al.
Diabetes, Obesity & Metabolism|January 26, 2018
Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanismEric Zijlstra, Hans-Veit Coester, Tim Heise, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Drugs & Aging|November 23, 2016
A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes MellitusTim Heise, Ulrike Hövelmann, Eric Zijlstra, et al.
Journal of Diabetes Science and Technology|November 3, 2022
An Investigation Into Local Infusion Site Pain After Infusion of Ultra Rapid Lispro Excipients Across Sites and DepthsDebra Ignaut, Tsuyoshi Fukuda, Ramanjineyulu Bandi, et al.
Diabetes, Obesity & Metabolism|February 21, 2024
Pharmacokinetic and pharmacodynamic properties of once-weekly insulin icodec in individuals with type 1 diabetesUlrike Hövelmann, Susanne Engberg, Tim Heise, et al.
Clinical Pharmacokinetics|November 24, 2016
Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes MellitusTim Heise, Kirstine Stender-Petersen, Ulrike Hövelmann, et al.
Journal of Diabetes Science and Technology|April 27, 2023
Noninvasive Continuous Glucose Monitoring With a Novel Wearable Dial Resonating Sensor: A Clinical Proof-of-Concept StudyConsuelo Handy, Mohamed Sabih Chaudhry, Muhammad Rafaqat Ali Qureshi, et al.
Journal of Diabetes Science and Technology|December 28, 2022
Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 DiabetesParag Garhyan, Edward Pratt, Oliver Klein, et al.
Clinical Therapeutics|September 9, 2020
Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy SubjectsJennifer Leohr, Mary Anne Dellva, Elizabeth LaBell, et al.
Diabetology & Metabolic Syndrome|December 5, 2017
Poor glycaemic control is associated with reduced exercise performance and oxygen economy during cardio-pulmonary exercise testing in people with type 1 diabetesOthmar Moser, Max L Eckstein, Olivia McCarthy, et al.
Diabetes, Obesity & Metabolism|October 10, 2023
Ultra rapid lispro (Lyumjev®) shortens time to recovery from hyperglycaemia compared to Humalog® in individuals with type 1 diabetes on continuous subcutaneous insulin infusionJennifer Leohr, Mary Anne Dellva, Elizabeth LaBell, et al.
Diabetes, Obesity & Metabolism|January 26, 2018
Injecting without pressing a button: An exploratory study of a shield-triggered injection mechanismEric Zijlstra, Hans-Veit Coester, Tim Heise, et al.
Pageof 3